News
BCTX
1.100
+1.85%
0.020
HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $15 Price Target
Benzinga · 1h ago
Promising Phase 2 Results and Safety Profile Justify Buy Rating for BriaCell Therapeutics
TipRanks · 2h ago
BriaCell 7.4M share Spot Secondary priced at 75c
TipRanks · 2h ago
Why DBV Technologies Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Benzinga · 2h ago
BriaCell Prices 7.4 Mln Public Offering, To Raise $5.5 Mln
NASDAQ · 5h ago
Reported Earlier, BriaCell Therapeutics Prices $5.5M Public Offering Of 7.4M Shares At $0.75/Share For Working Capital Requirements
Benzinga · 6h ago
BriaCell Therapeutics slumps 29%, prices $5.55M stock offering
Seeking Alpha · 7h ago
BRIACELL THERAPEUTICS CORP - PRICES PUBLIC OFFERING OF 7.4 MLN SHARES AND WARRANTS AT $0.75 EACH
Reuters · 8h ago
BriaCell Therapeutics Plans Public Offering
TipRanks · 15h ago
BriaCell Therapeutics announces proposed public offering, shares fall
Seeking Alpha · 16h ago
BriaCell announces common shares, warrants offering
TipRanks · 16h ago
BriaCell Therapeutics Intends To Offer To Sell Common Shares And Warrants In Public Offering; No Terms Disclosed
Benzinga · 16h ago
BRIACELL THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING
Reuters · 16h ago
BriaCell Therapeutics Announces Proposed Public Offering
Barchart · 22h ago
BriaCell Shows Promising Survival Data in Cancer Trial
TipRanks · 1d ago
BriaCell presents OS data in MBC patients treated with Bria-IMT/CPI regimen
TipRanks · 1d ago
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Barchart · 1d ago
Briacell Therapeutics Corp <BCT.TO> expected to post a loss of 8 cents a share - Earnings Preview
Reuters · 1d ago
Weekly Report: what happened at BCTX last week (1202-1206)?
Weekly Report · 3d ago
News Movers: Yesterday’s Hottest News That Could Move the Needle Today
Barchart · 12/05 01:38
More
Webull provides a variety of real-time BCTX stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.
About BCTX
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.